

Cover Story
Regulatory News
The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic castration-resistant prostate cancer patients whose tumors have a BRCA mutation.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for May 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?